1220P A randomized phase II trial of anlotinib plus docetaxel vs docetaxel for second-line treatment of EGFR-negative NSCLC (ALTER-L018)

MLA

Z. Wu, et al. “1220P A Randomized Phase II Trial of Anlotinib plus Docetaxel vs Docetaxel for Second-Line Treatment of EGFR-Negative NSCLC (ALTER-L018).” Annals of Oncology, vol. 32, Sept. 2021, p. S970. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.08.1825.

APA

Z. Wu, M. Xiao, Kang Li, Y. Cao, Y. Chen, H. Duan, Z. Ma, Xingxiang Pu, Q. Wang, J. Weng, Jianjun Li, Zefen Xiao, Peiguo Cao, Yujin Xu, Huilai Zhang, & Lingqian Wu. (2021). 1220P A randomized phase II trial of anlotinib plus docetaxel vs docetaxel for second-line treatment of EGFR-negative NSCLC (ALTER-L018). Annals of Oncology, 32, S970. https://doi.org/10.1016/j.annonc.2021.08.1825

Chicago

Z. Wu, M. Xiao, Kang Li, Y. Cao, Y. Chen, H. Duan, Z. Ma, et al. 2021. “1220P A Randomized Phase II Trial of Anlotinib plus Docetaxel vs Docetaxel for Second-Line Treatment of EGFR-Negative NSCLC (ALTER-L018).” Annals of Oncology 32 (September): S970. doi:10.1016/j.annonc.2021.08.1825.